Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
– Net revenue rose 81% from prior quarter to $58.7 million – – CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter – – UDENYCA® autoinjector launched in late May, and YUSIMRY™ launched in July – – Planned merger with Surface Oncology …